QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=8024CB861F67EABF3542FC05E9ADF376;jsessionid=E6E189B5D4EC9EA760E7188A55E488D8;jsessionid=A4133546448B55D6FA1A59D6DF673F7D;jsessionid=5F419476EB394D0397E93C98FD281388;jsessionid=2CEE1FEE538B7986617370979D2883B8;jsessionid=312D2B6A68AA1F890F8F1AB7B51811B6;jsessionid=5E2A70567B13FC58F9289D50010F5B66;jsessionid=7F9D7E843520605ACADC252F5DE131BA (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=8024CB861F67EABF3542FC05E9ADF376;jsessionid=E6E189B5D4EC9EA760E7188A55E488D8;jsessionid=A4133546448B55D6FA1A59D6DF673F7D;jsessionid=5F419476EB394D0397E93C98FD281388;jsessionid=2CEE1FEE538B7986617370979D2883B8;jsessionid=312D2B6A68AA1F890F8F1AB7B51811B6;jsessionid=5E2A70567B13FC58F9289D50010F5B66;jsessionid=7F9D7E843520605ACADC252F5DE131BA